From GlobeNewswire: 2024-03-27 06:40:00

Cellectar Biosciences reported positive results from their clinical trials focusing on the treatment of cancer, particularly Waldenstrom’s macroglobulinemia. The pivotal study showed a major response rate of 61% in patients who received at least two prior lines of therapy. The company also announced strategic partnerships and promising preclinical data for additional cancer treatments.

The company’s Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer showed a 64% Complete Remission rate and a 73% Overall Response Rate. The company continues to focus on developing innovative treatments for various types of cancer, with ongoing clinical trials and research efforts.

Cellectar Biosciences reported a pathological response with complete clonal clearance in a relapsed/refractory Waldenstrom’s macroglobulinemia patient with CNS involvement, enrolled in its Phase 2b CLOVER WaM pivotal trial. The company also enrolled the first patient in a Phase 1b clinical study of iopofosine I 131 in pediatric high-grade gliomas (pHGG) supported by a $2 million Fast Track SBIR grant.

The company expanded its Intellectual Property protection for its PDC Platform to deliver flavaglines as targeted anticancer payloads, with patent allowances in key global regions. Financially, Cellectar had cash and cash equivalents of $9.6 million as of December 31, 2023, with net cash used in operating activities of approximately $32.4 million. The company’s net loss attributable to common stockholders for the year ended December 31, 2023, was ($38.0) million.



Read more at GlobeNewswire:: Cellectar Biosciences Reports Financial Results for Year